KVUE Stock Dips After Court Revives Tylenol Autism Lawsuits

• A three-judge panel of the 2nd U.S. Circuit Court of Appeals overturned parts of a lower court’s dismissal of the cases.
• The appeals court said the lower court was wrong to block key expert testimonies but upheld the exclusion of two other experts.
• Kenvue says extensive research does not show that Tylenol causes autism or ADHD.

Kenvue Inc. (KVUE) shares fell about 2% on Monday after a federal appeals court ruled that the company must face lawsuits claiming Tylenol use during pregnancy can raise the risk of autism and ADHD in children.

Court Ruling

A three-judge panel of the 2nd U.S. Circuit Court of Appeals overturned parts of a lower court’s dismissal of the cases. The appeals court said the lower court was wrong to block key expert testimonies but upheld the exclusion of two other experts. It sent the cases back to the lower court for further review.

The ruling also rejected arguments that federal rules prevented the lawsuits from moving forward.

Allegations And Kenvue’s Response

Hundreds of families claim Kenvue failed to warn pregnant women that acetaminophen — the active ingredient in Tylenol — could increase the chances of their children developing autism or ADHD. A lower court had dismissed the cases in 2023, ruling that the scientific evidence presented was not reliable enough to proceed.

Kenvue says extensive research does not show that Tylenol causes autism or ADHD. The FDA requires only a general pregnancy warning on acetaminophen products and does not mandate specific warnings for these conditions.

The decision adds legal uncertainty for Kenvue at a time when Tylenol remains one of its flagship consumer health brands. Kenvue does not segment its Tylenol revenue separately, but its pain care segment, under which Tylenol falls, accounted for 13% of Kenvue's total net sales in 2025.

How Did KVUE Retail Traders React?

On Stocktwits, retail sentiment around KVUE stock stayed within the ‘neutral’ territory over the past 24 hours, while message volume remained at ‘normal’ levels.

According to data from Koyfin, 12 of the 14 analysts covering KVUE rate it 'Hold,' while two rate it 'Buy' or higher. The 12-month average price target on the stock is $19.58, representing a potential upside of about 0.5% from the stock’s closing price on Friday.

KVUE stock has gained over 11% year-to-date. 

Read More: Paramount-Warner Bros Discovery’s $110B Merger Hits A New Hurdle As California, 11 Other States Sue To Block It

For updates and corrections, email newsroom[at]stocktwits[dot]com.